Triple

T10292160
Position Surface form Disambiguated ID Type / Status
Subject bortezomib E241388 entity
Predicate metabolizingEnzyme P37221 FINISHED
Object CYP3A4 E242412 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CYP3A4 | Statement: [bortezomib, metabolizingEnzyme, CYP3A4]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: CYP3A4
Context triple: [bortezomib, metabolizingEnzyme, CYP3A4]
  • A. CYP3A4 chosen
    CYP3A4 is a major human liver and intestinal enzyme of the cytochrome P450 family responsible for metabolizing a wide range of drugs and xenobiotics.
  • B. CYP1A2
    CYP1A2 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs and xenobiotics.
  • C. CYP2C19
    CYP2C19 is a liver enzyme of the cytochrome P450 family that plays a key role in the metabolism of various drugs, including certain antidepressants, proton pump inhibitors, and antiplatelet agents.
  • D. CYP2C9
    CYP2C9 is a liver enzyme of the cytochrome P450 family that plays a key role in metabolizing various drugs, including many nonsteroidal anti-inflammatory agents and anticoagulants.
  • E. CYP2D6
    CYP2D6 is a highly polymorphic cytochrome P450 enzyme that plays a major role in the metabolism of many drugs, contributing significantly to interindividual variability in drug response.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: metabolizingEnzyme
Context triple: [bortezomib, metabolizingEnzyme, CYP3A4]
  • A. isMetabolizedBy chosen
    Indicates that a substance is biochemically broken down or transformed through metabolic processes carried out by a specified organism, cell type, or enzyme system.
  • B. isMetabolizedPrimarilyIn
    Indicates that the substance undergoes its main metabolic processing within the specified biological system or organ.
  • C. enzymeType
    Indicates the specific class or category of enzyme associated with an entity or reaction.
  • D. enzymeSystem
    Indicates a relationship where an entity functions as, or is part of, a specific enzyme system involved in catalyzing biochemical reactions.
  • E. metabolismType
    Indicates the kind of metabolic process or pathway an entity uses to obtain and transform energy or nutrients.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d381aaafc08190af475ef58dc16aba completed April 6, 2026, 9:49 a.m.
NER Named-entity recognition batch_69d4d2d35f048190a215493acdf1f718 completed April 7, 2026, 9:48 a.m.
NED1 Entity disambiguation (via context triple) batch_69d7500fdd1c81909395469afb346f8b completed April 9, 2026, 7:06 a.m.
PD Predicate disambiguation batch_69d4d1f35e548190be3b4d92d65d2d20 completed April 7, 2026, 9:44 a.m.
Created at: April 6, 2026, 11:42 a.m.